在晚期多发性骨髓瘤中,骨解性骨损伤的分子基础的解
Dongyeop Shin1, Myung-Jin Kim2, Soyeon Chun3
1Department of Internal Medicine, Seoul National University Hospital, Seoul 03080.
Haematologica
|January 11, 2024
概括
在多发性骨髓瘤 (MM) 患者中,Fms类铁酶3连接体 (FLT3L) 的升高与骨解性骨损伤有关. 这种FLT3L-STAT3-DKK1通路抑制骨形成,表明FLT3L是MM骨病的生物标志物和治疗标.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 骨的新陈代谢 骨的新陈代谢
背景情况:
- 骨解性骨损伤显著损害了多发性骨髓瘤 (MM) 的生活质量和预后.
- 在MM中驱动骨解的分子机制尚未完全理解.
- 在患有骨质溶解的晚期MM患者中,Fms类铁酸酶3连接体 (FLT3L) 的含量升高.
研究的目的:
- 研究FLT3L在MM患者骨解骨过程中的功能性作用.
- 探索将FLT3L与骨质溶解联系起来的分子途径.
- 评估FLT3L作为MM相关骨病变的潜在生物标志物和治疗标.
主要方法:
- 从MM,AML和ALL患者的骨髓血中测量FLT3L水平.
- 使用体外基于细胞的试验 (HEK293T,HeLa,U2OS) 来评估FLT3L对DKK1表达和WNT信号传递的影响.
- 分析了MM亚型的转录形状.
主要成果:
- 与AML和ALL患者相比,MM患者的FLT3L水平显著更高.
- 在MM患者中,FLT3L水平升高与骨病变存在相关.
- 通过STAT3酸化,FLT3L的使用增加了DKK1转录水平,并抑制了WNT信号传递,这表明它在骨解中发挥了作用.
- FLT3L和DKK1主要在超化MM亚型中升高.
结论:
- FLT3L-STAT3-DKK1通路抑制了WNT信号传递,导致MM的骨解性骨病变.
- FLT3L作为一个有前途的生物标志物,用于预测MM的骨解性骨病变.
- FLT3L代表了一种潜在的治疗点,用于管理高二倍化MM的骨解性进展.
相关概念视频
01:31Osteoclasts in Bone Remodeling
2.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
2.9K
01:40Bone Remodeling
38.3K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
38.3K